Moleculin Gets Trial Participation Request from 14 Qualified Clinical Sites

Moleculin Biotech (NASDAQ:MBRX) announced a total of 14 cancer clinics requested to participate in their clinical trial to study Annamycin for treating acute myeloid leukemia.
As quoted in the press release:

“We’ve had a very positive response from the hematology oncology community,” commented Walter Klemp, Chairman and CEO of Moleculin. “With little to no cardiotoxicity and a structure that has been shown to avoid the multidrug resistance mechanisms that often defeat the current first line standard of care for AML, a number of clinicians recognize that Annamycin could provide a second chance to patients who have run out of options.”
Mr. Klemp continued: “We are pleased to have so many sites express interest in this trial, as it should help improve our chances for timely patient recruitment. In addition, seven of these interested sites are in Poland where we believe we will have access to a higher percentage of patients who are what we call ‘treatment naive’, meaning they have not been subjected to any experimental therapies before entering our trial.”

Click here to read the full press release.

Source: www.marketwired.com